

This is a repository copy of Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/161968/</u>

Version: Accepted Version

Article:

Espensen, CA, Kiilgaard, JF, Appelt, AL orcid.org/0000-0003-2792-9218 et al. (5 more authors) (2021) Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas. Ophthalmology, 128 (1). pp. 152-161. ISSN 0161-6420

https://doi.org/10.1016/j.ophtha.2020.06.030

© 2020 by the American Academy of Ophthalmology. This is an author produced version of an article published in Ophthalmology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Supplementary material

Appendix A: Treatment details

Each patient had four tantalum clips surgically sutured onto the sclera surrounding the tumour borders. The surgeries were performed under general anesthesia, and transillumination was used to visualize the tumour. The thickness and diameter of the tumour were reported from subsequent ultrasound scan.

Tumour contouring was based on pre-treatment retinographies including a 2.5 mm margin surrounding the tumour. The retina, macula, optic disc, globe, ciliary body, cornea and lens were all contoured as well. Tumour coverage was highest priority during all treatments. When possible and without compromising tumour coverage, macula and optic nerve sparing were prioritized by carrying out proton plan optimization using gazing angle, margins and/or filter.

The proton therapy treatment was carried out two to four weeks after clip placement. During treatment, the patients were seated with the head immobilized by a specially designed facemask and bite block. Orientation of the eye in the correct angle was achieved by a light-emitting diode. X-ray images was used to position the clips (and thus the tumour) correctly in the beam during dosimetry. The position and movement of the eye was observed by video camera during treatment, which was disrupted if eye movements occurred.

Complication/outcome	Dose to structure*	Clinical factors	Analysis	Patients
Visual acuity deterioration	Retina (surface)	Age, gender,	Logistic	i. 551
i. Pre-treatment VA better	Macula (volume)	tumour height,	regression	
than 0.5 logMAR. Post-	Optic disc (surface)	tumour-optic disc		ii. 1020
treatment VA increase of	Globe (volume)	distance, pre-		
0.3 logMAR compared	Ciliary body (volume)	treatment VA and		
to initial	Cornea (surface)	follow-up time		
ii. All patients regardless of	Lens (volume)			
initial visual acuity.				
Post-treatment VA				
increase of 0.3 logMAR				
compared to initial				
Maculopathy	Retina (surface)	Age, gender,	Cox regression	991
Includes both ischemia and	Macula (volume)	tumour height,	analysis.	
edema in the macular region	Optic disc (surface)	tumour-optic disc	Censoring:	
as defined in the database	Globe (volume)	distance	death from any	
	Ciliary body (volume)		cause, lost to	
			follow-up,	
			relapse or	
			enucleation	
Optic neuropathy	Retina (surface)	Age, gender,	Cox regression	991
An oedemic, atrophic,	Macula (volume)	tumour height,	analysis.	
undelimited and/or pale	Optic disc (surface)	tumour-optic disc	Censoring:	
	Globe (volume)	distance	death from any	

optic disc as defined in the	Ciliary body (volume)		cause, lost to	
database			follow-up,	
			relapse or	
			enucleation	
Catanat				001
Cataract	Globe (volume)	Age, gender,	Cox regression	991
Includes only the radiation	Ciliary body (volume)	tumour height,	analysis.	
induced cataracts as defined	Cornea (surface)	tumour-optic disc	Censoring:	
in the database	Lens (volume)	distance	death from any	
			cause, lost to	
			follow-up,	
			relapse or	
			enucleation	
Neovascular glaucoma	Retina (surface)	Age, gender,	Cox regression	991
Includes the neovascular	Optic disc (surface)	tumour height,	analysis.	
glaucomas as defined in the	Ciliary body (volume)	tumour-optic disc	Censoring:	
database	Cornea (surface)	distance	death from any	
	Globe (volume)		cause, lost to	
			follow-up,	
			relapse or	
			enucleation	
Dry eye	Globe (volume)	Age, gender,	Cox regression	991
Includes all with dry eye as	Cornea (surface)	tumour height,	analysis.	
defined in the database		tumour-optic disc	Censoring:	
		distance	death from any	
			cause, lost to	
			follow-up,	

		relapse or	
		enucleation	
Retina (surface)	Age, gender,	Logistic	991
	tumour height,	regression	
	tumour-optic disc		
	distance		
Retina (surface)	Age, gender,	Cox regression	991
Optic disc (volume)	tumour height,	analysis.	
Ciliary body (volume)	tumour-optic disc	Censoring:	
Cornea (surface)	distance	death from any	
		cause, lost to	
		follow-up,	
		relapse or	
		enucleation.	
Retina (surface)	Age, gender,	Cox regression	991
Macula (volume)	tumour height,	analysis.	
Optic disc (volume)	tumour-optic disc	Censoring:	
Globe (volume)	distance	death from any	
Ciliary body (volume)		cause, lost to	
		follow-up,	
		relapse or	
		1	1
	Retina (surface) Optic disc (volume) Ciliary body (volume) Cornea (surface) Retina (surface) Macula (volume) Optic disc (volume) Globe (volume)	Retina (surface)Age, gender,Optic disc (volume)tumour-optic discCiliary body (volume)tumour-optic discCornea (surface)distanceRetina (surface)Age, gender,Macula (volume)tumour height,Optic disc (volume)tumour height,Cornea (surface)Age, gender,Macula (volume)tumour height,Optic disc (volume)tumour optic discGlobe (volume)distance	Retina (surface)Age, gender, tumour height, tumour-optic disc distanceLogistic regressionRetina (surface)Age, gender, distanceCox regressionOptic disc (volume)tumour height, tumour height,analysis.Ciliary body (volume)tumour height, distancecensoring: follow-up, relapse or enucleation.Retina (surface)Age, gender, tumour height,Censoring: follow-up, relapse or enucleation.Retina (surface)Age, gender, distanceCensoring: follow-up, relapse or enucleation.Retina (surface)Age, gender, tumour height, ifollow-up, relapse or

*Dose to specific volumes/surface of the structure ($D_{2\%}$, $D_{20\%}$, $D_{50\%}$, $D_{98\%}$) will be used in the model. Furthermore, we will include volume/surface that receives a specific dose (V/S_{5Gy}, V/S_{10Gy}, V/S_{26Gy}, V/S_{42Gy}, V/S_{52Gy}).

Appendix C: Model performance

Hosmer-Lemeshow was used to evaluate the model performance of the logistic regressions. Figure C1 illustrates the results. The p-values of p=0.27 for pre-treatment visual acuity loss and p=0.05 for visual acuity deterioration indicate that there was no significant difference between the observed and expected risk for pre-treatment visual acuity loss and visual acuity deterioration, respectively.




Figure C1: A) Hosmer-Lemeshow calibration comparing the observed risk of visual acuity deterioration group with the fitted probabilities expected from the logistic model (group 1, analysis 1). Number of groups was set to 25. B) Same for loss of good pre-treatment visual acuity (group 1, analysis 2).




Figure C2: Hosmer-Lemeshow calibration comparing the observed risk of loss of pre-treatment visual acuity with the fitted probabilities expected from the logistic model. Number of groups was set to 25.

Concordance index was calculated for all Cox regression models to evaluate the model performance.

Complication	5-year c-index	5-year Brier score
Maculopathy	53.8 %	0.164
Optic neuropathy	76.9 %	0.109
Neovascular glaucoma	83.8 %	0.082
Cataract	63.2 %	0.196
Ocular hypertension	80.1 %	0.062

Table C1: Concordance index for each complication at 5-years




Figure C3: Concordance index plotted for each of the late complications for a 10-year period.